Serum surfactant protein D: Biomarker of chronic obstructive pulmonary disease

Disease Markers

Volumn 32, Issue 5, 2012, Pages 281-287

  Ju, Chun Rong ^a   Liu, Wei ^a   Chen, Rong Chang ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

airflow limitation; BODE index; COPD; exacerbation; surfactant protein D (SP D)

Indexed keywords

C REACTIVE PROTEIN; SURFACTANT PROTEIN D;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; BLOOD ANALYSIS; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE MARKER; DISEASE SEVERITY; DYSPNEA; EXERCISE; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPIROMETRY;

EID: 84861514320     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.3233/DMA-2011-0887     Document Type: Article

References (40)

1. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis, Thorax 59 (2004), 574-580. (Pubitemid 38901515)
2. Barnes PJ, Celli BR. Systemic manifestations and comorbidi-ties of COPD, Eur Respir J 33 (2009), 1165-1185.
3. Maclay JD, McAllister DA, Mills NL, et al. Vascular dysfunction in chronic obstructive pulmonary disease, Am J Respir Crit Care Med 180 (2009), 513-520.
4. Agusti AG, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease, Eur Respir J 21 (2003), 347-360. (Pubitemid 36204553)
5. Emiel F. M. Wouters1, Karin H. et al. Systemic inflammation in chronic obstructive pulmonary disease: The role of exacerbations, Proc Am Thorac Soc 4 (2007), 626-634.
6. Kersul AL, Iglesias A, Ŕios A, Molecular mechanisms of inflammation during exacerbations of chronic obstructive pulmonary disease, Arch Bronconeumol 47 (2011), 176-183.
7. Hurst JR, Perera WR, Wilkinson TM, et al. Exacerbation of chronic obstructive pulmonary disease: pan-airway and systemic inflammatory indices, Proc Am Thorac Soc 3 (2006), 481-482. (Pubitemid 44285524)
8. Palaniyar N, Zhang L, Kuzmenko A, et al. The role of pulmonary collectin N-terminal domains in surfactant structure, function, and homeostasis in vivo, J Biol Chem 277 (2002), 26971-26979. (Pubitemid 34951708)
9. Kawasaki Y, Endo K, Suyama K, Sato M, Ito M, Hashimoto K, Hosoya M. Serum SP-D levels as a biomarker of lung injury in respiratory syncytial virus bronchiolitis, Pediatr Pulmonol 46 (2011), 18-22.
10. Ohnishi H, Yokoyama A, Kondo K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases, Am J Respir Crit Care Med 165 (2002), 378-381. (Pubitemid 34118512)
11. Eisner MD, Parsons P, Matthay MA, et al. Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. Thorax 58 (2003), 983-988. (Pubitemid 37392811)
12. Krane M, Griese M. Surfactant protein D in serum from patients with allergic bronchopulmonary aspergillosis. Eur Respir J 22 (2003), 592-595. (Pubitemid 37258535)
13. Shakooria TA, Sin DD, Ghafoor F, et al. Serum surfactant protein D during acute exacerbations of chronic obstructive pulmonary disease, Dis Markers 27 (2009), 287-294.
14. Sin DD, Pahlvan PS, Man SFP. Review: Surfactant protein D: A lung specific biomarker in COPD? Ther Adv Resp Dis 2 (2008), 65-74 (Pubitemid 351472132)
15. Global Initiative for Chronic Obstructive Lung Disease. Available at: www.goldcopd.com. Accessed March 11, (2008).
16. Celli BR, Cote CG, Mari'n JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease, N Engl J Med 350 (2004), 1005-1012. (Pubitemid 38269277)
17. Mahler D, Wells C. Evaluation of clinical methods for rating dyspnea, Chest 93 (1988), 580-586.
18. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories: ATS statement: guidelines for the six minute walk test, Am J Respir Crit Care Med 166 (2002), 111-117.
19. Doyle IR, Nicholas TE, Bersten AD. Surfactant proteins A and B are elevated in plasma of patients with acute respiratory failure, Am J Respir Crit Care Med 12004 (1997), 1217-1229.
20. Robin M, Dong P, Hermans C, et al. Serum levels of CC16, SP-A and SP-B reflect tobacco-smoke exposure in asymptomatic subjects, Eur Respir J 20 (2002), 1152-1161. (Pubitemid 35331872)
21. Hermans C, Bernard A. Lung epithelium-specific proteins: characteristics and potential applications as markers, Am J Respir Crit Care Med 159 (1999), 646-678.
22. Hartl D, Griese M. Surfactant protein D in human lung diseases, Eur J Clin Invest 36 (2006), 423-435. (Pubitemid 43742701)
23. Winkler C, Atochina-Vasserman EN, Holz O, et al. Comprehensive characterisation of pulmonary and serum surfactant protein D in COPD, Respir Res 12 (2011), 29.
24. Sin DD, Man S-FP, Marciniuk DD, et al. The effects of flu-ticasone with or without salmeterol on systemic biomarkers of inflammation in COPD, Am J Respir Crit Care Med 177 (2008), 1207-1214. (Pubitemid 351860929)
25. Perera WR, Hurst JR, Wilkinson TM, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation, Eur Respir J 29 (2007), 527-534. (Pubitemid 46372101)
26. Müller B, Tamm M. Biomarkers in acute exacerbation of chronic obstructive pulmonary disease: among the blind, the one-eyed is king, Am J Respir Crit Care Med 174 (2006), 848-849. (Pubitemid 44564781)
27. Ruiz-González A, Lacasta D, Ibarz M, et al. C-reactive protein and other predictors of poor outcome in patients hospitalized with exacerbations of chronic obstructive pulmonary disease, Respirology 13 (2008), 1028-1033.
28. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations, Am J Respir Crit Care Med 173 (2006), 1114-1121. (Pubitemid 43726892)
29. Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease, Am J Respir Crit Care Med 174 (2006), 867-874. (Pubitemid 44564786)
30. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 111 (2003), 1805-1812. (Pubitemid 38057722)
31. Mold C, Rodic-Polic B, Du Clos TW. Protection from Streptococcus pneumoniae infection by C-reactive protein and natural antibody requires complement but not Fc receptors, J Immunol 168 (2002), 6375-6381. (Pubitemid 34620061)
32. Hasegawa M, Fujimoto M, Hamaguchi Y, et al. Use of serum clara cell 16-kDa (CC16) levels as a potential indicator of active pulmonary fibrosis in systemic sclerosis, J Rheumatol 38 (2011), 877-884.
33. Kawasaki Y, Endo K, Suyama K, et al. Serum SP-D levels as a biomarker of lung injury in respiratory syncytial virus bronchiolitis, Pediatr Pulmonol 46 (2011), 18-22.
34. Singh D, Edwards L, Tal-Singer R, et al. The radiological patterns of interstitial change at an early phase: over a 4-year follow-up, Respir Res 11 (2010), 77.
35. Bonella F, Volpe A, Caramaschi P, et al. Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement, Sarcoidosis Vasc Diffuse Lung Dis 28 (2011), 27-33.
36. Osaka A, Yanagihara K, Yamada Y, et al. Elevation of serum KL-6 glycoprotein or surfactant protein-D in adult T-cell leukemia with distinct pulmonary complications, Tohoku J Exp Med 218 (2009), 99-105.
37. Lomas DA, Silverman EK, Edwards LD, et al. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD, Eur Respir J 34 (2009), 95-102.
38. Sin DD, Leung R, Gan WQ, et al. Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study, BMC Pulm Med 7 (2007), 13.
39. Ong KC, Lu SJ, Soh CS. Does the multidimensional grading system (BODE) correspond to differences in health status of patients with COPD? Int J Chron Obstruct Pulmon Dis 1 (2006), 91-96.
40. Ong KH, Earnest A, Lu SJ. A multidimensional grading system (BODE index) as a predictor of hospitalization for COPD, Chest 128 (2005), 3310-3316.